Drug intelligence / Profile preview

CAR19TIF

Development stage: Phase 2
Lead developer: Chinese PLA General Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

CAR19TIF is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19. It is engineered with knockouts of the BCOR and ZC3H12 genes, which are intended to confer "immortal-like and functional" characteristics to the T cells, enhancing their expansion and persistence and reducing T cell exhaustion. This therapy is being evaluated for safety and efficacy in patients with refractory/relapsed B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia (B-ALL).

Other names: immortal-like and functional CD19 CAR T cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CAR19TIF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR19TIF.

Explore the full profile